Opus Genetics, Inc.
Moat Score — Opus Genetics, Inc.
Total Moat Score
9 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Opus holds patents and regulatory designations (RMAT, orphan, rare pediatric) covering its lead OPGx-LCA5 gene therapy and licensed intellectual property for OPGx-BEST1 and OPGx-RHO from Iveric Bio and UPenn, plus patents behind its already-approved RYZUMVI mydriasis-reversal drug. The RYZUMVI patents are real but currently being directly challenged by Sandoz's Paragraph IV filing, which tempers the score. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a clinical-stage biotech with no owned manufacturing and a reliance on contract manufacturers and academic partners, Opus has no unit-cost advantage over any competitor; it is not pursuing a low-cost strategy in any of its markets. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | RYZUMVI, as an FDA-approved branded therapy with no direct generic yet on the market, commands premium pricing through its partner Viatris, but Sandoz's pending ANDA/Paragraph IV challenge and the small, specialized mydriasis-reversal market cap how much pricing power the asset can sustainably exercise. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Neither the gene-therapy pipeline nor the small-molecule ophthalmic portfolio exhibits any network or platform dynamic; each product's value is self-contained and does not increase as more patients or physicians adopt it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Once a patient has been dosed with an AAV-based gene therapy like OPGx-LCA5, there is no 'switching' in the conventional sense since treatment is intended to be one-time, so this category is better read as low-relevance; for the small-molecule franchise, physicians and patients face minimal switching friction if a generic or competing presbyopia drop like VUITY becomes available. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | Opus targets ultra-rare, genetically defined retinal diseases (LCA5, BEST1) where patient populations are small enough that the company describes no known direct competitor — a classic efficient-scale niche too narrow to attract most large pharmaceutical competitors, though academic and smaller biotech rivals (MeiraGTX, Octant Bio) are active in adjacent IRD genes. |